Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of YH001 capsules in severe alopecia areata
CTR20244367Phase 2Suspended
- Sponsor
- Hangzhou Yuhong Pharmaceutical Technology
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YH001 in alopecia areata, sponsored by Hangzhou Yuhong Pharmaceutical Technology. Started Dec 2024; status: suspended.
02
Drugs
YH001
03
Conditions
alopecia areata
Beyond the preview
Go deeper on CTR20244367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244367.